You are here

Article Text

Article menu
Download PDFPDF
Letter
Is stool DNA multitarget testing an unreliable strategy for colorectal cancer screening?
  1. G Ferretti1,
  2. E Bria1,
  3. P Carlini1,
  4. A Felici1,
  5. D Giannarelli2,
  6. F Cuppone3,
  7. P Papaldo3,
  8. C Nisticò3,
  9. A Fabi3,
  10. A Gelibter3,
  11. E Terzoli3,
  12. F Cognetti3
  1. 1Department of Medical Oncology, Regina Elena Cancer Institute, Rome, Italy
  2. 2Biostatistics Unit, Regina Elena Cancer Institute, Rome, Italy
  3. 3Department of Medical Oncology, Regina Elena Cancer Institute, Rome, Italy
  1. Correspondence to:
    Dr G Ferretti
    Department of Medical Oncology, Regina Elena Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy; gia.fer{at}flashnet.it

https://doi.org/10.1136/gut.2005.066951

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The availability of a simple non-invasive test capable of detecting colorectal cancer specific products with reasonable sensitivity and specificity might avoid the invasiveness, unpleasant bowel preparation, and risk of bleeding and perforation related to colonoscopy. Molecular marker combinations in faecal DNA testing have been shown to produce high rates of both colorectal cancer and advanced adenoma detection in selected patient populations,1 and observations from large representative groups are emerging.

    Imperiale and colleagues2 …

    View Full Text

    Footnotes

    • Conflict of interest: None declared.